Newsmax TV & Webwww.newsmax.comFREE - In Google Play
Newsmax TV & Webwww.newsmax.comFREE - On the App Store

New Psoriasis Drug Shows Promise

Tuesday, 25 October 2011 10:26 AM EDT

Rapid and significant relief of moderate-to-severe psoriasis symptoms has been reported in trials of the new Novartis drug AIN457, the pharmaceutical company says.

In one study, 81 percent of patients receiving AIN457 subcutaneously once a month showed at least a 75 percent improvement – compared to just 9 percent improvement by the group receiving a placebo after 12 weeks.

"We are encouraged by these positive Phase II results and look forward to receiving the results of larger-scale and longer-term Phase III studies with AIN457 which began this year," said John Hohneker, global head of development for integrated hospital care at Novartis.

AIN457 is a human antibody designed to suppress the inflammation involved in a number of immune-mediated diseases, including psoriasis.

Psoriasis is a common hereditary disease characterized by thick skin lesions called plaques. Symptoms associated with the lesions including itching, scaling, and pain. Psoriasis affects about 2 percent of the world’s population.

© HealthDay

Tuesday, 25 October 2011 10:26 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
You May Also Like
Get Newsmax Text Alerts

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

© Newsmax Media, Inc.
All Rights Reserved
© Newsmax Media, Inc.
All Rights Reserved